Bio-Rad's Q4 2024 Earnings Call: Diverging Views on Digital PCR Growth, Chromatography Recovery, and Life Sciences Orders
Earnings DecryptThursday, Feb 13, 2025 11:50 pm ET

These are the key contradictions discussed in Bio-Rad Laboratories' latest 2024Q4 earnings call, specifically including: Digital PCR Growth Expectations, Process Chromatography Destocking and Recovery, and Life Sciences Order Trends and Funnel Activity:
Revenue Performance:
- Bio-Rad Laboratories reported net sales for the fourth quarter of 2024 at $668 million, representing a 2% decline on a reported basis and a 2.3% year-over-year decrease on a currency-neutral basis.
- This decline was mainly due to lower sales in the Life Science segment, which experienced a 5.5% decline on a reported basis and 6% on a currency-neutral basis.
Segment Performance:
- The Life Science Group sales were $275 million in Q4 2024, compared to $291 million in Q4 2023, showing a decline of 5.5% on a reported basis and 6% on a currency-neutral basis.
- The Clinical Diagnostics Group registered an increase of 0.9% on a reported basis and 0.7% on a currency-neutral basis, driven by increased demand for quality control and blood typing products.
Operational and Strategic Initiatives:
- Bio-Rad achieved gross margin expansion in 2024 through lean initiatives and rationalization of its global footprint, which is expected to continue in 2025.
- The company entered into an agreement to acquire Stilla Technologies, aimed at enhancing its digital PCR portfolio and expanding its product strategy in applied research and clinical diagnostics.
Financial Outlook:
- For 2025, Bio-Rad is projecting a currency-neutral revenue growth between 1.5% and 3.5%, with an expected non-GAAP gross margin between 55% and 55.5%.
- The guidance contemplates continued softness in academic and biopharma markets, with a focus on operational excellence and cost management.
Revenue Performance:
- Bio-Rad Laboratories reported net sales for the fourth quarter of 2024 at $668 million, representing a 2% decline on a reported basis and a 2.3% year-over-year decrease on a currency-neutral basis.
- This decline was mainly due to lower sales in the Life Science segment, which experienced a 5.5% decline on a reported basis and 6% on a currency-neutral basis.
Segment Performance:
- The Life Science Group sales were $275 million in Q4 2024, compared to $291 million in Q4 2023, showing a decline of 5.5% on a reported basis and 6% on a currency-neutral basis.
- The Clinical Diagnostics Group registered an increase of 0.9% on a reported basis and 0.7% on a currency-neutral basis, driven by increased demand for quality control and blood typing products.
Operational and Strategic Initiatives:
- Bio-Rad achieved gross margin expansion in 2024 through lean initiatives and rationalization of its global footprint, which is expected to continue in 2025.
- The company entered into an agreement to acquire Stilla Technologies, aimed at enhancing its digital PCR portfolio and expanding its product strategy in applied research and clinical diagnostics.
Financial Outlook:
- For 2025, Bio-Rad is projecting a currency-neutral revenue growth between 1.5% and 3.5%, with an expected non-GAAP gross margin between 55% and 55.5%.
- The guidance contemplates continued softness in academic and biopharma markets, with a focus on operational excellence and cost management.

Disclaimer: The news articles available on this platform are generated in whole or in part by artificial intelligence and may not have been reviewed or fact checked by human editors. While we make reasonable efforts to ensure the quality and accuracy of the content, we make no representations or warranties, express or implied, as to the truthfulness, reliability, completeness, or timeliness of any information provided. It is your sole responsibility to independently verify any facts, statements, or claims prior to acting upon them. Ainvest Fintech Inc expressly disclaims all liability for any loss, damage, or harm arising from the use of or reliance on AI-generated content, including but not limited to direct, indirect, incidental, or consequential damages.
Comments
No comments yet